-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38

Benzinga·08/13/2026 12:57:04
Listen to the news
Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raises the price target from $36 to $38.